Rosa Segarra

627 total citations
12 papers, 476 citations indexed

About

Rosa Segarra is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Molecular Biology. According to data from OpenAlex, Rosa Segarra has authored 12 papers receiving a total of 476 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 5 papers in Physiology and 1 paper in Molecular Biology. Recurrent topics in Rosa Segarra's work include Chronic Obstructive Pulmonary Disease (COPD) Research (10 papers), Asthma and respiratory diseases (4 papers) and Respiratory and Cough-Related Research (3 papers). Rosa Segarra is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (10 papers), Asthma and respiratory diseases (4 papers) and Respiratory and Cough-Related Research (3 papers). Rosa Segarra collaborates with scholars based in Spain, Poland and Germany. Rosa Segarra's co-authors include Esther García Gil, Cynthia Caracta, Gonzalo de Miquel, Rosa Lamarca, Jutta Beier, Anne‐Marie Kirsten, Paul Jones, Àlvar Agustí, Eric Bateman and Dave Singh and has published in prestigious journals such as European Respiratory Journal, Thorax and Drug Metabolism and Disposition.

In The Last Decade

Rosa Segarra

12 papers receiving 447 citations

Peers

Countries citing papers authored by Rosa Segarra

Since Specialization

Citations

This map shows the geographic impact of Rosa Segarra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rosa Segarra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rosa Segarra more than expected).

Fields of papers citing papers by Rosa Segarra

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rosa Segarra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rosa Segarra. The network helps show where Rosa Segarra may publish in the future.

Co-authorship network of co-authors of Rosa Segarra

This figure shows the co-authorship network connecting the top 25 collaborators of Rosa Segarra. A scholar is included among the top collaborators of Rosa Segarra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rosa Segarra. Rosa Segarra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	<p>AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD</p> 2019 ·International Journal of COPD ·Sanjay Sethi, Edward Kerwin, Henrik Watz, Gary T. Ferguson, Robert Mróz, Rosa Segarra, Eduard Molins, Diana Jarreta, Esther García Gil	16
2	Efficacy and safety of aclidinium/formoterolversussalmeterol/fluticasone: a phase 3 COPD study 2016 ·European Respiratory Journal ·Claus Vogelmeier, Pier Luigi Paggiaro, Jordi Dorca, Paweł Śliwiński, (unknown), Anne‐Marie Kirsten, Jutta Beier, Beatriz Seoane, Rosa Segarra, Anne Leselbaum	75
3	Efficacy of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in COPD 2015 ·Claus Vogelmeier, Pier Luigi Paggiaro, Jordi Dorca, Paweł Śliwiński, (unknown), Anne‐Marie Kirsten, Beatriz Seoane, Rosa Segarra, Anne Leselbaum, Esther García Gil	6
4	Overall and cardiovascular safety of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in patients with COPD 2015 ·Jutta Beier, Claus Vogelmeier, Robert Mróz, Sergi Pascual-Guàrdia, Rosa Segarra, (unknown), Gonzalo de Miquel	3
5	Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study 2013 ·European Respiratory Journal ·Jutta Beier, Anne‐Marie Kirsten, Robert Mróz, Rosa Segarra, Ferran Chuecos, Cynthia Caracta, Esther García Gil	2
6	Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: A phase IIIb study 2013 ·European Respiratory Journal ·Jutta Beier, Anne‐Marie Kirsten, Robert Mróz, Rosa Segarra, Ferran Chuecos, Cynthia Caracta, Esther García Gil	1
7	Efficacy and Safety of Aclidinium Bromide Compared with Placebo and Tiotropium in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: Results from a 6-week, Randomized, Controlled Phase Iiib Study 2013 ·COPD Journal of Chronic Obstructive Pulmonary Disease ·Jutta Beier, Anne‐Marie Kirsten, Robert Mróz, Rosa Segarra, Ferran Chuecos, Cynthia Caracta, Esther García Gil	87
8	Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study 2012 ·European Respiratory Journal ·Paul Jones, Dave Singh, Eric Bateman, Àlvar Agustí, Rosa Lamarca, Gonzalo de Miquel, Rosa Segarra, Cynthia Caracta, Esther García Gil	141
9	S51 Efficacy of Aclidinium Bromide Compared with Tiotropium and Placebo in Patients with Moderate to Severe COPD: A Phase IIIb Study: Abstract S51 Table 1 2012 ·Thorax ·Jutta Beier, Anne Kirsten, Robert Mróz, Rosa Segarra, Ferran Chuecos, Cynthia Caracta, Esther García Gil	3
10	Lung Deposition of Aclidinium Bromide from Genuair®, a Multidose Dry Powder Inhaler 2009 ·Respiration ·Stephen P. Newman, (unknown), Rosa Segarra, Rosa Lamarca, Gonzalo de Miquel	43
11	The Prokinetic Cinitapride Has No Clinically Relevant Pharmacokinetic Interaction and Effect on QT during Coadministration with Ketoconazole 2007 ·Drug Metabolism and Disposition ·(unknown), (unknown), Rosa Segarra, Marco Pavesi, (unknown), David Roberts, Georg Golor	19
12	Consistent Efficacy and Tolerability of Almotriptan in the Acute Treatment of Multiple Migraine Attacks: Results of a Large, Randomized, Double-Blind, Placebo-Controlled Study 2000 ·Cephalalgia ·Julio Pascual, (unknown), (unknown), A Prusiński, (unknown), (unknown), (unknown), (unknown), Rosa Segarra, (unknown)	80

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact